Citadel Advisors’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.66M | Buy |
115,300
+5,900
| +5% | +$466K | ﹤0.01% | 3454 |
|
|
2025
Q4 | $8.65M | Sell |
109,400
-400
| -0.4% | -$30.1K | ﹤0.01% | 3448 |
|
|
2025
Q3 | $7.18M | Buy |
109,800
+19,700
| +22% | +$962K | ﹤0.01% | 3746 |
|
|
2025
Q2 | $3.56M | Buy |
90,100
+12,100
| +16% | +$396K | ﹤0.01% | 4686 |
|
|
2025
Q1 | $2.35M | Buy |
78,000
+40,600
| +109% | +$1.33M | ﹤0.01% | 5226 |
|
|
2024
Q4 | $1.31M | Sell |
37,400
-19,500
| -34% | -$729K | ﹤0.01% | 6492 |
|
|
2024
Q3 | $2.28M | Sell |
56,900
-88,300
| -61% | -$4.11M | ﹤0.01% | 5292 |
|
|
2024
Q2 | $6.92M | Buy |
145,200
+7,400
| +5% | +$304K | ﹤0.01% | 3280 |
|
|
2024
Q1 | $5.97M | Buy |
137,800
+91,400
| +197% | +$4.36M | ﹤0.01% | 3660 |
|
|
2023
Q4 | $2.35M | Buy |
46,400
+12,100
| +35% | +$580K | ﹤0.01% | 5086 |
|
|
2023
Q3 | $1.56M | Sell |
34,300
-16,700
| -33% | -$689K | ﹤0.01% | 5688 |
|
|
2023
Q2 | $2.09M | Buy |
51,000
+43,700
| +599% | +$1.68M | ﹤0.01% | 5076 |
|
|
2023
Q1 | $261K | Sell |
7,300
-28,000
| -79% | -$1.05M | ﹤0.01% | 9674 |
|
|
2022
Q4 | $1.33M | Sell |
35,300
-15,000
| -30% | -$631K | ﹤0.01% | 6263 |
|
|
2022
Q3 | $2.23M | Sell |
50,300
-1,100
| -2% | -$46.3K | ﹤0.01% | 5391 |
|
|
2022
Q2 | $1.9M | Buy |
51,400
+13,700
| +36% | +$517K | ﹤0.01% | 5637 |
|
|
2022
Q1 | $1.4M | Sell |
37,700
-36,500
| -49% | -$1.19M | ﹤0.01% | 6902 |
|
|
2021
Q4 | $2.26M | Buy |
74,200
+3,000
| +4% | +$94.4K | ﹤0.01% | 5962 |
|
|
2021
Q3 | $2.39M | Sell |
71,200
-34,800
| -33% | -$1.31M | ﹤0.01% | 5912 |
|
|
2021
Q2 | $4.23M | Sell |
106,000
-11,000
| -9% | -$431K | ﹤0.01% | 4806 |
|
|
2021
Q1 | $5.26M | Sell |
117,000
-13,100
| -10% | -$731K | ﹤0.01% | 4142 |
|
|
2020
Q4 | $7.36M | Buy |
130,100
+58,100
| +81% | +$2.9M | ﹤0.01% | 3063 |
|
|
2020
Q3 | $3.42M | Sell |
72,000
-1,400
| -2% | -$77.8K | ﹤0.01% | 3757 |
|
|
2020
Q2 | $4.33M | Buy |
73,400
+7,700
| +12% | +$428K | ﹤0.01% | 3281 |
|
|
2020
Q1 | $3.11M | Buy |
65,700
+15,300
| +30% | +$853K | ﹤0.01% | 3407 |
|
|
2019
Q4 | $3.04M | Sell |
50,400
-33,000
| -40% | -$1.97M | ﹤0.01% | 3764 |
|
|
2019
Q3 | $5M | Sell |
83,400
-31,400
| -27% | -$2.05M | ﹤0.01% | 3114 |
|
|
2019
Q2 | $7.38M | Buy |
114,800
+62,900
| +121% | +$4.45M | ﹤0.01% | 2557 |
|
|
2019
Q1 | $4.21M | Sell |
51,900
-13,700
| -21% | -$884K | ﹤0.01% | 3248 |
|
|
2018
Q4 | $3.55M | Sell |
65,600
-113,200
| -63% | -$5.77M | ﹤0.01% | 3296 |
|
|
2018
Q3 | $9.22M | Buy |
178,800
+113,600
| +174% | +$5.34M | ﹤0.01% | 2198 |
|
|
2018
Q2 | $2.72M | Buy |
65,200
+3,900
| +6% | +$173K | ﹤0.01% | 3629 |
|
|
2018
Q1 | $2.7M | Buy |
61,300
+24,700
| +67% | +$1.25M | ﹤0.01% | 3281 |
|
|
2017
Q4 | $1.84M | Sell |
36,600
-37,800
| -51% | -$2.07M | ﹤0.01% | 3751 |
|
|
2017
Q3 | $3.77M | Buy |
74,400
+19,900
| +37% | +$1.04M | ﹤0.01% | 2626 |
|
|
2017
Q2 | $2.77M | Sell |
54,500
-3,900
| -7% | -$182K | ﹤0.01% | 2755 |
|
|
2017
Q1 | $2.35M | Sell |
58,400
-38,000
| -39% | -$1.71M | ﹤0.01% | 2893 |
|
|
2016
Q4 | $4.61M | Sell |
96,400
-3,200
| -3% | -$127K | ﹤0.01% | 2092 |
|
|
2016
Q3 | $3.65M | Buy |
99,600
+23,900
| +32% | +$748K | ﹤0.01% | 2292 |
|
|
2016
Q2 | $1.76M | Buy |
75,700
+15,100
| +25% | +$487K | ﹤0.01% | 2877 |
|
|
2016
Q1 | $2.45M | Buy |
+60,600
| New | +$2.46M | ﹤0.01% | 2440 |
|
|
2015
Q4 | – | Sell |
-51,200
| Closed | -$2.07M | – | 8925 |
|
|
2015
Q3 | $2.07M | Sell |
51,200
-1,000
| -2% | -$51.8K | ﹤0.01% | 2895 |
|
|
2015
Q2 | $3M | Sell |
52,200
-9,300
| -15% | -$591K | ﹤0.01% | 2582 |
|
|
2015
Q1 | $3.92M | Sell |
61,500
-2,800
| -4% | -$190K | ﹤0.01% | 2293 |
|
|
2014
Q4 | $3.97M | Buy |
64,300
+9,300
| +17% | +$459K | ﹤0.01% | 2195 |
|
|
2014
Q3 | $2.14M | Buy |
55,000
+20,700
| +60% | +$734K | ﹤0.01% | 2788 |
|
|
2014
Q2 | $1.18M | Sell |
34,300
-14,500
| -30% | -$457K | ﹤0.01% | 3288 |
|
|
2014
Q1 | $2.11M | Sell |
48,800
-5,300
| -10% | -$257K | ﹤0.01% | 2601 |
|
|
2013
Q4 | $2.15M | Sell |
54,100
-10,200
| -16% | -$363K | ﹤0.01% | 2478 |
|
|
2013
Q3 | $2.41M | Buy |
64,300
+20,100
| +45% | +$600K | ﹤0.01% | 2234 |
|
|
2013
Q2 | $1.19M | Buy |
+44,200
| New | +$940K | ﹤0.01% | 3013 |
|
Other funds holding IONS
VPM
VCM
Citadel Advisors's IONS Position: Q1 2026 in Review
Citadel Advisors reduced its Ionis Pharmaceuticals (IONS) stake by 56% in Q1 2026, selling an estimated $94.1M and leaving 942,534 shares worth $70.8M. The position accounts for 0.01% of the portfolio, ranked #1072.
Citadel Advisors first reported a position in IONS in Q2 2013 and has held it in 47 quarters since. The position peaked at $169M in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- Citadel Advisors held 942,534 shares of Ionis Pharmaceuticals worth $70.8M as of Q1 2026.
- Citadel Advisors sold 1,192,102 Ionis Pharmaceuticals shares in Q1 2026, an estimated $94.1M.
- Ionis Pharmaceuticals made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1072 holding.
- Citadel Advisors first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 47 quarters since.
- Citadel Advisors's Ionis Pharmaceuticals position peaked at $169M in Q4 2025.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.